Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL709637 | 1.00 | LMNA (0.46) | LMNAPOLBALDH1A1SCN9APKM | |
| SCHEMBL419701 | 1.00 | LMNA (0.46) | LMNAPOLBALDH1A1SCN9APKM | |
| SCHEMBL4640252 | 0.94 | LMNA (0.41) | LMNAPOLBALDH1A1SCN9ASMN1; SMN2 | |
| SCHEMBL709307 | 0.94 | LMNA (0.41) | LMNAPOLBALDH1A1SCN9ASMN1; SMN2 | |
| SCHEMBL8709127 | 0.94 | LMNA (0.41) | LMNAPOLBALDH1A1SCN9ASMN1; SMN2 | |
| SCHEMBL20266437 | 0.90 | LMNA (0.36) | LMNAPOLBALDH1A1SCN9ATSHR | |
| SCHEMBL12747032 | 0.90 | LMNA (0.36) | LMNAPOLBALDH1A1SCN9ATSHR | |
| SCHEMBL26687025 | 0.84 | LMNA (0.49) | LMNAPOLBALDH1A1SCN9APKM | |
| SCHEMBL2198401 | 0.81 | ALDH1A1 (0.39) | LMNAPOLBALDH1A1SCN9APKM | |
| SCHEMBL15074098 | 0.81 | ALDH1A1 (0.39) | LMNAPOLBALDH1A1SCN9APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110068-A1 | Lithium secondary cell | MITSUBISHI CHEMICAL CORPORATION (JP) | 2004-06-10 | — | — | US | claimed |
| EP-1406338-A1 | LITHIUM SECONDARY CELL | MITSUBISHI CHEMICAL CORPORATION (JP) | 2004-04-07 | — | — | EP | claimed |
| WO-2025122695-A1 | COMBINATION THERAPY COMPRISING DGK INHIBITORS AND PD-1/PD-L1 INHIBITORS | INCYTE CORPORATION (US) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025043151-A2 | BICYCLIC DGK INHIBITORS | INCYTE CORPORATION (US) | 2025-02-27 | — | — | WO | disclosed |
| CN-113121393-B | Aromatic amide compound and application thereof in medicines | 广东东阳光药业股份有限公司 | 2024-08-09 | — | — | CN | disclosed |
| US-20240066027-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2024-02-29 | — | — | US | disclosed |
| US-20240051951-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2024-02-15 | — | — | US | disclosed |
| EP-4255904-A2 | NOVEL PAR-2 INHIBITORS | Domain Therapeutics (FR) | 2023-10-11 | — | — | EP | disclosed |
| US-20230286965-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-09-14 | — | — | US | disclosed |
| US-11725001-B2 | Bicyclic compound and use thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-08-15 | — | — | US | disclosed |
| US-20230013903-A1 | Electrolytic Solution for Secondary Battery and Lithium Secondary Battery Including the Same | SK ON CO., LTD. (KR) | 2023-01-19 | — | — | US | disclosed |
| EP-0389037-B1 | N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1995-09-20 | — | — | EP | disclosed |
| US-5374637-A | Stimulate gastrointestinal motility | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-12-20 | — | — | US | disclosed |
| US-5262418-A | Laxatives, gastrointestinal disorders | TANSSEN PHARMACEUTICA N.V. (BE) | 1993-11-16 | — | — | US | disclosed |
| US-5185335-A | Administer to mammals to stimulate gastrointestinal motility | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-02-09 | — | — | US | disclosed |
| EP-0445862-A2 | N-(4-piperidinyl)(dihydrobenzofuran or dihydro-2H-benzopyran)carboxamide derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-09-11 | — | — | EP | disclosed |
| EP-0389037-A1 | N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-09-26 | — | — | EP | disclosed |
| EP-0213775-B1 | NEW BENZAMIDES | WALTON S.A. (ES) | 1990-01-03 | — | — | EP | disclosed |
| US-4772618-A | NONAROMATIC CYCLIC (THIO)ETHER GROUPS, AMINE INTERMEDIATES, GASTROINTESTINAL DISORDERS | FORDONAL, S.A. (ES) | 1988-09-20 | — | — | US | disclosed |
| EP-0213775-A1 | New Benzamides | WALTON S.A. (ES) | 1987-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240051951-A1 | BICYCLIC COMPOUND AND USE THEREOF | PRMT5, PRMT6, PRMT1 | LMNA 1399/4885POLB 2256/4885ALDH1A1 3781/4885 |
| US-20230286965-A1 | BICYCLIC COMPOUND AND USE THEREOF | PRMT5, PRMT6, PRMT8 | LMNA 1468/4885POLB 2109/4885ALDH1A1 4003/4885 |
| US-11725001-B2 | Bicyclic compound and use thereof | PRMT5, PRMT6, PRMT1 | LMNA 1399/4885POLB 2256/4885ALDH1A1 3781/4885 |
| US-20240066027-A1 | NOVEL PAR-2 INHIBITORS | F2RL1, F2R, F2RL3 | LMNA 1935/4885POLB 4651/4885ALDH1A1 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.